Dendreon Corporation is a biotechnology company that specializes in the development of immunotherapy products for the treatment of cancer. Its flagship product is called Provenge, a drug that has been approved by the FDA for the treatment of prostate cancer. Uses: Provenge is designed to stimulate the immune system to specifically attack cancer cells in the body. It is used to treat prostate cancer that has not spread to other parts of the body, and has stopped responding to hormone therapy. Dosage: The dosing regimen for Provenge is unique, as the drug is customized for each individual patient. The patient’s own white blood cells are collected and then treated with Provenge to create a personalized vaccine. The vaccine is then infused back into the patient over a course of three treatments, each two weeks apart. Side effects: The most common side effects of Provenge are flu-like symptoms that develop within a day or two of treatment. These may include fever, chills, fatigue, nausea, joint pain, and headache. These symptoms typically resolve within a few days on their own. Provenge does not typically cause the hair loss, vomiting or other types of side effects that are commonly associated with chemotherapy. Interactions: There are no known drug interactions with Provenge at this time. However, patients should always inform their doctors of all medications they are currently taking before starting any new treatment. Generic: There is currently no generic version of Provenge, as the product is highly specialized and requires individual customization for each patient. Demographic: Prostate cancer primarily affects men over the age of 50, with the majority of cases diagnosed in men over age 65. Provenge is specifically indicated for men with prostate cancer that has not responded to hormone therapy and that has not yet spread to other parts of the body. In conclusion, Dendreon Corporation’s Provenge is a unique and effective treatment for prostate cancer that has not responded to traditional therapies. While the dosing regimen is personalized for each patient, the most common side effects are mild and short-lived. Patients and their doctors can be assured of the drug’s safety and efficacy, as it has been approved by the FDA for use in this patient population. With no known drug interactions and no generic version available, Provenge remains a valuable treatment option for men with advanced prostate cancer.